FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.
3 reports, 2 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Syndax Pharmaceuticals
business
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Simply Wall St.Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted? Syndax Pharmaceuticals, Inc. recently reported its second quarter 2025 results, with revenue r
- Insider MonkeyFDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the 11 Best Short-Term Stocks to Invest in. Amid revenu
- Unknown outlet